NETLIST Loses Three Federal Circuit Appeals Against Micron on Same Day
The Federal Circuit affirmed PTAB rulings invalidating claims of five Netlist memory patents challenged by Micron, including one precedential decision.
POLESTAR Posts $842M Half-Year Loss as Revenue Slips 4.4%
The EV maker cut its net loss by 29% in H1 2026, but adjusted EBITDA worsened to a loss of $521 million while deliveries were roughly flat.
CAMPBELL'S Cuts Dividend 36% and Guides FY27 EPS Down as Much as 24%
Q4 adjusted EPS fell 37% to $0.39, the quarterly payout drops to $0.25, and Campbell's targets $500 million in cost savings by fiscal 2030.
CIENA Revenue Jumps 37% to $1.67B as AI Drives Optical Demand
Ciena posted record fiscal Q3 revenue of $1.67 billion and adjusted EPS of $2.11, and raised its full-year revenue outlook to $6.42 billion.
APOGEE THERAPEUTICS Buyout Closes as Shares Head for Delisting
An 8-K filing shows Apogee Therapeutics has completed a change-of-control transaction, replaced its board and recapitalized to just 1,000 shares.
ELASTIC Founder Shay Banon Sells $44.5M in Shares Over Three Days
Elastic's CTO and co-founder disposed of about 476,000 ordinary shares between August 31 and September 2, cutting his stake to roughly 1.58 million shares.
Aura Minerals Director Sells $10.4 Million of Shares in Open Market
A Form 4 shows director Bruno Sousa Mauad sold 127,500 Aura Minerals shares at $81.20 apiece on Aug. 31, cutting his stake by more than 40%.
CrowdStrike Co-Founder Kurtz and Director Gandhi Sell $8.8M in Stock
Two CrowdStrike insiders sold a combined 40,000 Class A shares on Aug. 31 and Sept. 1 at prices between roughly $213 and $234.
NESR CEO Sherif Foda Sells $3.5M in Stock, Gifts 675,000 Shares
National Energy Services Reunited's chief executive sold 100,000 ordinary shares at $35.00 and transferred another 675,000 shares as a gift.
FDA Approves Rasonque, First RAS Inhibitor for Metastatic Pancreatic Cancer
The FDA cleared daraxonrasib for the most common form of advanced pancreatic cancer, acting months ahead of its review deadline.
FDA Approves Lisraya, First Oral Drug for Dermatomyositis in Adults
The FDA has cleared Lisraya (brepocitinib) tablets, the first oral therapy specifically indicated for adults with dermatomyositis.
FDA Approves Mimrylo (Rusfertide), First Hepcidin Mimetic for Polycythemia Vera
The FDA has cleared Mimrylo (rusfertide) for adults with polycythemia vera, calling it the first drug of its kind for the rare blood disorder.